Baudax Bio, Inc.

The momentum for this stock is not very good. Baudax Bio, Inc. is a mediocre stock to choose.

News

Baudax Bio announces corporate update, to initiate development of TI-168

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Baudax Bio Announces Corporate Update

Globe Newswire Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In...\n more…

Why Is Baudax Bio (BXRX) Stock Up 75% Today?

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nAlthough Baudax Bio saw significant interest because of its orphan drug designation, BXRX stock must climb a wall of worry.\nThe post Why...\n more…

Baudax Bio shares rocket as lead clinical candidate granted FDA orphan drug designation

Proactive Investors - UK Baudax Bio shares rocket as lead clinical candidate granted FDA orphan drug designation...\n more…

Baudax Bio announces ODD granted by U.S. FDA for TI-168

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

Globe Newswire MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the Company or Baudax Bio ) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor ( TCR ) therapies...\n more…